| # | Title | Journal | Year | Citations |
|---|
| 1 | Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) | Biology of Blood and Marrow Transplantation | 2014 | 141 |
| 2 | Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes | Clinical Cancer Research | 2013 | 61 |
| 3 | Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties | Bone Marrow Transplantation | 2019 | 59 |
| 4 | Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years | Leukemia Research | 2008 | 36 |
| 5 | Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation | Bone Marrow Transplantation | 2017 | 30 |
| 6 | Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia | Annals of Hematology | 2002 | 28 |
| 7 | Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia | International Journal of Molecular Medicine | 2019 | 27 |
| 8 | Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes | Leukemia | 2019 | 25 |
| 9 | Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives | Journal of Clinical Medicine | 2020 | 21 |
| 10 | Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel) | Annals of Hematology | 2016 | 19 |
| 11 | RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? | Case Reports in Oncology | 2021 | 18 |
| 12 | Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome | Leukemia and Lymphoma | 2019 | 17 |
| 13 | Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients | Leukemia | 2016 | 16 |
| 14 | Advances in CMV Management: A Single Center Real-Life Experience | Frontiers in Cell and Developmental Biology | 2020 | 16 |
| 15 | BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing? | Blood | 2015 | 12 |
| 16 | A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia | Leukemia | 2003 | 11 |
| 17 | Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients | Blood | 2018 | 11 |
| 18 | Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis | Blood | 2013 | 11 |
| 19 | S883 COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY | HemaSphere | 2019 | 10 |
| 20 | A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation | Frontiers in Immunology | 2020 | 10 |
| 21 | BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE | Mediterranean Journal of Hematology and Infectious Diseases | 2016 | 9 |
| 22 | CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. | Mediterranean Journal of Hematology and Infectious Diseases | 2019 | 9 |
| 23 | A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients | Blood | 2010 | 9 |
| 24 | Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients | Leukemia | 2008 | 8 |
| 25 | Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System | Scientific Reports | 2019 | 8 |
| 26 | Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties | Blood | 2016 | 8 |
| 27 | Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease | Blood | 2008 | 8 |
| 28 | ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial | Case Reports in Hematology | 2020 | 7 |
| 29 | A Blood Bank Standardized Production of Human Platelet Lysate for Mesenchymal Stromal Cell Expansion: Proteomic Characterization and Biological Effects | Frontiers in Cell and Developmental Biology | 2021 | 6 |
| 30 | Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study | Blood | 2016 | 6 |
| 31 | Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? | Frontiers in Oncology | 2020 | 5 |
| 32 | Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood? | British Journal of Haematology | 2020 | 5 |
| 33 | Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509 | Blood | 2011 | 5 |
| 34 | Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) | Blood | 2019 | 3 |
| 35 | Low-Dose Rituximab in Idiopathic Autoimmune Hemolytic Anemia. | Blood | 2009 | 3 |
| 36 | Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. | Blood | 2009 | 3 |
| 37 | In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) | Blood | 2012 | 3 |
| 38 | Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study | Blood | 2014 | 3 |
| 39 | Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease | Blood | 2014 | 3 |
| 40 | Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience | Blood | 2018 | 3 |
| 41 | Management of Invasive Infections due to a Rare Arthroconidial Yeast, Saprochaete capitata, in Two Patients with Acute Hematological Malignancies | Vaccines | 2021 | 3 |
| 42 | Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells | Cancer Chemotherapy and Pharmacology | 2006 | 2 |
| 43 | FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience | American Journal of Hematology | 2009 | 2 |
| 44 | Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) | Blood | 2018 | 2 |
| 45 | Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients | Blood | 2019 | 2 |
| 46 | Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies | Blood | 2012 | 2 |
| 47 | Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications | Blood | 2012 | 2 |
| 48 | Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients | Blood | 2014 | 2 |
| 49 | Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression | Blood | 2015 | 2 |
| 50 | Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study | Blood Research | 2020 | 2 |
